Related Experiment Videos
Effect of testosterone on bone in hypogonadal males
G Isaia1, M Mussetta, F Pecchio
1Clinica Medica B, University of Turin, Italy.
Maturitas
|August 1, 1992
Summary
Hypogonadal males have low bone mineral content (BMC). Testosterone therapy improved BMC and bone metabolism markers, suggesting testosterone directly impacts bone cells and calcitonin secretion.
Area of Science:
- Endocrinology
- Bone Metabolism
- Andrology
Background:
- Male hypogonadism is associated with decreased testosterone levels.
- Low testosterone can negatively impact bone mineral content (BMC).
Purpose of the Study:
- To compare BMC and testosterone levels in hypogonadal males versus controls.
- To investigate the effects of testosterone administration on BMC and bone markers in hypogonadal males.
Main Methods:
- Comparative analysis of bone mineral content (BMC) and testosterone levels.
- Assessment of calcitonin (CT) response, osteocalcin (BGP), and urinary ratios before and after testosterone administration.
Main Results:
- Hypogonadal males exhibited significantly lower BMC compared to normal controls.
- Testosterone administration increased lumbar BMC and basal osteocalcin (BGP) levels.
- Testosterone therapy enhanced calcitonin (CT) response to hypercalcaemia.
Conclusions:
- Male hypogonadism is characterized by reduced bone mineral content (BMC).
- Testosterone therapy effectively improves BMC in hypogonadal males.
- Testosterone likely influences bone health through direct osteoblast action and improved CT secretion.